Overview

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.
Phase:
Phase 2
Details
Lead Sponsor:
Repros Therapeutics Inc.
Treatments:
Clomiphene
Enclomiphene
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Zuclomiphene